ETIDIOH - NEW

  Antiviral Res SCHRELL L, Scheibner D, Dickmanns A, Stegmann KM, et al Inhibitors of pyrimidine synthesis synergize with N4-hydroxycytidine to diminish influenza virus replication. Antiviral Res. 2025 Oct 3:106286. doi: 10.1016/j.antiviral.2025.106286. PubMed           Abstract available BMJ WISE J Covid-19: Excluding doctors from vaccination programme puts patients at risk, clinicians warn. BMJ. 2025;391:r2141. PubMed          Clin Infect Dis ATMAR RL, Abate G, Deming ME, George SL, et al Emerging and Pandemic Pathogens: Lessons Learned From a Clinical Research Network. Clin Infect Dis. 2025;81. PubMed           Abstract available JANO K, Babu TM, Kottkamp AC, Rebolledo PA, et al Historical Advances in Clinical Trial Design and Expanding Representation as the New Frontier for Innovation. Clin Infect Dis. 2025;81. PubMed         ...

  Ann Intern Med LE VU M, Matthes KL, Schneider EB, Moerlen A, et al Maternal Influenza-Like Illness and Neonatal Health During the 1918 Influenza Pandemic in a Swiss City. Ann Intern Med. 2025 Oct 7. doi: 10.7326/ANNALS-24-03796. PubMed           Abstract available Antiviral Res SCHRELL L, Scheibner D, Dickmanns A, Stegmann KM, et al Inhibitors of pyrimidine synthesis synergize with N4-hydroxycytidine to diminish influenza virus replication. Antiviral Res. 2025 Oct 3:106286. doi: 10.1016/j.antiviral.2025.106286. PubMed           Abstract available Epidemiol Infect VAN DER ROEST B, Fischer EAJ, Klinkenberg D, Bootsma MCJ, et al Phylodynamic inference suggests introductions as main driver of Mpox Clade II outbreak in 2022 in Slovenia. Epidemiol Infect. 2025;153:e115. PubMed           Abstract available WOLDEGIORGIS M, Bloomfield L, Korda R, Cadby G, et al Factors a...

  Summary Background Ensitrelvir is an oral antiviral treatment for COVID-19 with the same molecular target (the main protease ) as ritonavir-boosted nirmatrelvir —the current oral first-line treatment. We aimed to compare the clinical antiviral effects of the two drugs. Methods In an open-label, phase 2, randomised, controlled, adaptive pharmacometric platform trial, low-risk adult outpatients aged 18–60 years with early symptomatic COVID-19 (<4 days of symptoms) were recruited from hospital acute respiratory infection clinics in Thailand and Laos . Patients were randomly assigned in blocks (block sizes depended on the number of interventions available) to one of eight treatment groups, including oral ensitrelvir and oral ritonavir-boosted nirmatrelvir at standard doses, both given for 5 days, and no study drug. The primary endpoint was the oropharyngeal SARS-CoV-2 viral clearance rate assessed between day 0 and day 5 in the modified intention-to-treat population (defined as pa...

  By Dornicke - Own work, CC BY-SA 4.0,  https://commons.wikimedia.org/w/index.php?curid=5162139 Source: Wikipedia,  https://en.wikipedia.org/wiki/Henschel_%26_Son ____